Botulinum Toxin A in Treatment of Facial Flushing
Flushing is a condition with episodic attacks of redness of the skin with a sensation of warmth or burning, this disease causes emotional and functional problems in patients. There is various treatments for this condition; one of them is the use of botulinum toxin-A (BTA). In this prospective pilot study we studied the effect of Botulinum toxin-A (BTA) effect on DLQI of patients with facial flushing, we compared the DLQI before and after treatment. The number of 24 women with facial flushing admitted to the department of dermatology of Hamadan Farshchian Hospital, with the age range of 18 to 60 was enrolled in the study. Patients completed Dermatology Quality of life Index questionnaire before and one month after treatment. In our study 1 unit of BTA was injected intracutaneously per square cm in both sides of cheeks, to a total dose of 30 units per session. All of 24 patients completed the study. The mean age was 37.79±13.13. In all patients, DLQI decreased, and in two months follow up, the mean of DLQI improved from 8.08±1.17 to 4.5±1.21 (P.value<0.005). Based on this study BTA is an effective and safe treatment for facial flushing.
Boloux PM. sweating and flushing: evaluation and management. ENDO 2003:243-252.
Yuraitis M, Jacob CI. Botulinum Toxin for the Treatment of Facial Flushing. Dermatol Surg 2004;30:102–104.
Izikson L, English JC, Zirwas M.J. The flushing patient: Differential diagnosis, workup, and treatment. J Am Acad Dermatol 2006;55:193-208.
Oh YJ, Lee NY, Suh DH, Koh JS, Lee SJ, Shin MK. A split-face study using Botulinum Toxin type B to decrease facial Erythema index. Journal of Cosmetic Dermatology 2006; 5(3):268-272.
Wilkin JK. Why is flushing limited to a mostly facial cutaneous distribution. J Am Acad Dermatol 1988;19:309-12.
Sterodimas A, Nicolaou M, Paes TRF. Successful use of Botulinum toxin-A for the treatment of neckand anterior chest wall flushing. Clinical and Experimental Dermatology 2003:28, 592–594.
Friedman BS, Germano P, Miletti J, Metcalfe DD. A clinicopathologic study of ten patients with recurrent unexplained flushing. J ALLERGY CLIN IMMUNOL 1994;93:53-60.
Hashmonai M, Kopelman D, Assalia A. The Treatment of Primary Palmar Hyperhidrosis: A Review. Surg Today 2000; 30:211–218.
Companati A, Penna L, Guzzo T, Menotta L, BSilvestri B, Lagalla G, Gesuita R, Offidani A . Quality of life assessment in patients with hyperhidrosis before and after treatment with Botulinum toxin: Result of an open label study. Clin Ther 2003;25:298-308.
Parish LC, Witkkowski JA. Acne rosacea and Helicobacter pylori betrothed. Int J Dermatol 1995; 34:237-8.
Jansen T, Plewig G. Rosacea: classification and treatment. J R Soc Med 1997; 90(3): 144–150.
Kim WO, Kil HK, Yoon KB, Yoo JH. Treatment of Generalized Hyperhidrosis with Oxybutynin in Postmenopausal Patients. Acta Derm Venereol 2010; 90: 291–293.
Matarasso SL. Treatment of facial chromhidrosis withbotulinum toxin type A. J Am Acad Dermatol 2005;52:89-91.
Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administrationin therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53:407-15.
Cohen AA, Blitzer A. Botulinum toxin treatment for symptomatic Frey’s syndrome. Otolaryngol Head Neck Surg 2000;122:237-40.
Ferraro G, Altieri A, Grella E, D'Andrea F. Botulinum toxin: 28 patients affected by FREY’s syndrome treated with intradermal injections. Plastic and Reconstructive Surgery 2005;115(1):344-345.
Geddoa E, Matar HE, Paes TRF. The use of botulinum toxin-A in the management of neck and anterior chest wall flushing: pilot study. Int J Dermatol. 2013; 52(12):1547-50.
Dayan SH, Pritzker RN, Arkins JP. A New Treatment Regimen for Rosacea: OnabotulinumtoxinA. J Drugs Dermatol. 2012;11(12): 76-79.
Hekmann M, Ceballos Baumann AO, Plewig G. Botulinum toxin A or axillary hyperhidrosis ( excessive sweating ). N Engl J Med 2001: 344:488-93.
Cote TR, Mohan AK, Polder JA, Walton MK, Braun M. Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005;53:407-15.
Laing TA, Laing ME, O’Sullivan S.T. Botulinum toxin for treatment of glandular hypersecretory disorders. Journal of Plastic, Reconstructive & Aesthetic Surgery 2008; 61:1024-1028.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.